New combo therapy aims to wipe out hidden leukemia cells

This study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of a BTK inhibitor (acalabrutinib or zanubrutinib) with or without obinutuzumab will receive epcoritamab for 12 cycles. The goal is to see if this approach leads to undetectable minimal residual disease, meaning no cancer cells can be found in the blood.